Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.

Study Group: Generic Pharmaceuticals Regulation Experts: Healthcare Consultants

Council Members in this Study Group: 45

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Contact Gerson Lehrman Group to survey or consult with members of this Study Group

Leading institutions connect with members of this Study Group through GLG

Leading Experts in this Study Group

Eric Gruff, PhD MBA, Principal, E4 ConsultingEric Gruff, PhD MBA

Principal
E4 Consulting
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Eric Gruff, PhD, MBA, BS, is Founder of E4 Consulting, which specializes in pharmaceutical development, regulatory affairs, and project and portfolio management. Dr. Gruff has over 17 years of experience in the pharmaceutical and biotech sector, including leadership roles at Pfizer, Agouron Pharmaceuticals,...

11 recent news post(s)
Evan Siegel, MPhil, PhD

Adjunct Professor
THE UNIVERSITY OF QUEENSLAND
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Evan Siegel, M Phil, Ph D, is the President and Chief Executive Officer of Ground Zero Pharmaceuticals, a regulatory affairs and product development consulting firm in California, since June 1999. Dr. Siegel is also an Adjunct Professor at the University of Queensland, since November 2006. He provides...

8 recent news post(s)
1 recent event(s)
David Zimmerman, PharmD

President/Owner
Doctors of Pharmacy, Inc.
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

David Zimmerman, PharmD, FASCP, is the President and an Independent Consultant of Doctors of Pharmacy. Dr. Zimmerman formerly served as the Director of Clinical Affairs at Employee Health Insurance Management, a pharmacy benefit manager. He has over 30 years of experience, specializing in pharmacyservices...

9 recent news post(s)
Michael Sosnowik, RPh, PD

President
MSS Consultants, LLC
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Michael Sosnowik, PD, Pharmacist and former C-Level executive in pharma distribution, is the President of MSS Consultants, an independent consulting firm to pharmaceutical manufacturers, distributors as well as managed care providers, in New York, since September 2007. Previously, Mr. Sosnowik wasthe...

4 recent news post(s)
Jim Farley, President, Cardinal Consulting and TrainingJim Farley

President
Cardinal Consulting and Training
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Jim Farley is an Independent Consultant and Owner of Cardinal Consulting and Training. Formerly, Mr. Farley served as the Director of the Science Branch of Philadelphia District FDA. He has over 30 years of experience in pharmaceutical and pharmaceutical packaging industries with extensive experience...

2 recent news post(s)
Aemad Aslam, MBA

President
MindPharma
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Aemad Aslam, BPharm, MBA, RPh, is the President of MindPharma, a pharmacy and retail strategy consulting group. Most recently, he has consulted with a PBM, Prime Therapeutics, in Texas, a subsidiary of Blue Cross Blue Shield. He also has served as an Executive Team Leader for Pharmacy at the Target...

7 recent news post(s)
Nailesh Bhatt, Managing Director, PROXIMARE INCNailesh Bhatt

Managing Director
PROXIMARE INC
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Nailesh Bhatt is the Managing Director of Proximare, a leading strategy consulting firm that exclusively serves the pharmaceutical industry with offices in New Jersey and India, since June 2001. In this role, Mr. Bhatt works with senior pharmaceutical executives to develop and implement growth strategies...

2 recent news post(s)
Joseph Bertino, Pharm.D., Independent Consultant, Bertino ConsultingJoseph Bertino, Pharm.D.

Independent Consultant
Bertino Consulting
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Joseph Bertino, PharmD, is an Associate Professor of Pharmacology at Columbia University College of Physicians and Surgeons in New York. Through Bertino Consulting, he consults to the pharmaceutical industry in areas of infectious diseases, drug metabolism, and clinical pharmacology. Dr. Bertino'sresearch...

5 recent news post(s)

GLG NewsSM Analyses by this Study Group's Leading Experts (?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.

Thriving in a time of adversity - Sun Pharma pounces on shortage by getting approval on Oxycodone

April 13, 2009

Aemad Aslam, MBA, President, MindPharma

Sun Pharma gets USFDA's nod to market painkillers | www.hindu.com

Sun Pharma can greatly benefit from the nationwide shortage of Oxycodone Immediate Release Tablet, by getting approval from the FDA on their own generic. With recent recalls from different manufacturers, and the shortage of a comparable product Morphine Sulphate, the FDA currently estimates that return...

Aurobindo Pharma's Escitalopram will be a big mover ... when it comes out in 2011

March 5, 2009

Aemad Aslam, MBA, President, MindPharma

Aurobindo Pharma receives tentative approval for Escitalopram | www.indiainfoline.com

Forest's Lexapro commands a $2.5+ billion USD market share, just in the US.  Due to such a high volume of the brand product, Aurobindo's tentative approval on Lexapro's generic Escitalopram will be a great opportunity - primarily if they can procure a 6 month period of exclusivity from the FDA. ...

Teva's Generic Imitrex commands market of Sumatriptan

February 26, 2009

Aemad Aslam, MBA, President, MindPharma

Teva Announces Approval and Launch of Generic Imitrex(R) Tablets | www.pipelinereview.com

With the 180 day exclusivity, Teva is already commanding the market of the generic Imitrex - Sumatriptan oral tablets.  Teva maintains an AB rating of the generic that will render most insurance companies to push brand name Imitrex by GlaxoSmithKline to a non-formulary tier, skyrocketing the...

Acquisitions of Indian Pharma on the extended horizon by Brand name pharma

February 23, 2009

Aemad Aslam, MBA, President, MindPharma

Pharma cos on lookout for Indian drug firms | economictimes.indiatimes.com

Acquisitions of various Indian generic pharmaceuticals is likely on the horizon for brand name manufacturers.  However, this is not an immediate concern.  I would see more consolidations in the US and other Western markets first. 

Sun Pharma - much stronger with acquisitions including Taro

February 17, 2009

Aemad Aslam, MBA, President, MindPharma

As valuations dip, Sun Pharma is in M&A mode | economictimes.indiatimes.com

Sun Pharma is attempting to gain market share in the world largest market - the US market.  Sun Pharma is clearly expanding it product base with venturing into topical (dermatological) and pediatric segments, and with vertical integration as with raw materials suppliers.  Sequentially, Iwould...

View All GLG News by members of this Study Group

Members in this Study Group include these company types:

  • Consultancy, Pharma-Focused
  • Individual/Small Consultancy
  • Consultancy, Healthcare-Focused
  • Academic Institution*
  • Healthcare Management
  • Pharmaceuticals Manufacturer

Members in this Study Group often have these job titles:

  • President
  • Consultant
  • Principal
  • Owner
  • Professor
  • Director
  • Chief Executive Officer
  • Managing Director

Related Study Groups

Study Group Name No. Members
Generic Drug Economic Experts 767
Average Wholesale Pricing Economic Experts: Healthcare Consultants 20
Economic Experts on Pharmacy Benefit Management Services 79
Experts on Generic Pharmaceuticals: Pharmacists 107
Formulary Design Experts 252
Economic Experts on Managed Care 716
Pharmacists (US) 2079

GLG Live Meetings with this Study Group's Leading Experts (?)

Upcoming Seminars

Leading Experts in Generic Pharmaceuticals Regulation Experts: Healthcare Consultants Study Group have not participated in any upcoming seminars.

View All GLG Live Meetings in Healthcare

GLG Webcasts

Leading Experts in Generic Pharmaceuticals Regulation Experts: Healthcare Consultants have not participated in any GLG webcasts.

View All GLG Webcasts in Healthcare